Ketamine + Midazolam for Complex Regional Pain Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the effectiveness and safety of combining ketamine and midazolam infusions compared to midazolam alone for treating complex regional pain syndrome (CRPS). CRPS causes severe, persistent pain, often following an injury. Participants will receive infusions over five days to determine if these treatments can reduce pain. Individuals who have experienced CRPS-related pain for three months or more and can manage daily tasks like transportation may be suitable for this study. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that ketamine infusions can reduce pain in people with complex regional pain syndrome (CRPS). Some studies indicate that about 85% of patients experience pain relief after starting ketamine treatment. Most side effects are mild and manageable.
One study found ketamine to be safe, though some patients experienced side effects like changes in perception or mood, which were generally acceptable to those treated.
Midazolam, often used to reduce anxiety, is known to be safe. When combined with ketamine, it enhances comfort during treatment.
In summary, both ketamine and midazolam are generally safe, with side effects that most patients can manage.12345Why do researchers think this study treatment might be promising for complex regional pain syndrome?
Researchers are excited about using ketamine for Complex Regional Pain Syndrome (CRPS) because it targets pain differently than traditional treatments like physical therapy, nerve blocks, or opioids. Ketamine works by blocking NMDA receptors in the nervous system, which can help reset pain signals and potentially provide relief when other treatments fall short. Additionally, the combination with midazolam may enhance pain relief while minimizing the side effects often associated with ketamine. This approach offers a new avenue for CRPS management, with the potential for quicker and more significant pain reduction.
What evidence suggests that this trial's treatments could be effective for complex regional pain syndrome?
Research shows that ketamine, especially when combined with midazolam, can effectively reduce pain in people with complex regional pain syndrome (CRPS). In this trial, participants will receive either ketamine and midazolam infusions or midazolam and saline infusions. Studies have found that ketamine infusions help many patients manage pain better and improve their ability to function. Specifically, one study found that a 10-day ketamine infusion significantly reduced pain, while another study showed that 5 days of ketamine treatment provided noticeable pain relief. Using midazolam with ketamine has proven safe and without serious side effects. Although the pain relief might not last indefinitely, these treatments have given many people long-lasting improvements.13467
Who Is on the Research Team?
Theresa R Lii, MD, MS
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
Adults aged 18-65 with Complex Regional Pain Syndrome (CRPS) who've had pain for at least 3 months, can understand English questionnaires, and have a reliable adult to provide transportation during the trial. They must not be part of any group specifically excluded by the study's criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous infusions of ketamine and midazolam or midazolam and saline for 4 hours each day, over 5 consecutive days, in an outpatient setting
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ketamine and Midazolam Infusions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor